⚖ Oral Arguments, with Context

The Federal Circuit hears Acadia Pharmaceuticals’ patent dispute with generic drugmakers Aurobindo and MSN. The dispute concerns a small-capsule formulation of pimavanserin, a medicine used for hallucinations and delusions associated with Parkinson’s disease psychosis. The generic manufacturers pursued their own versions, and Acadia accused them of infringing its formulation patent. The patent’s requirements include granules—powder particles made to stick together—inside the capsule. After trial, a Delaware judge rejected the invalidity challenge and found Aurobindo’s proposed product infringed. Now the generic manufacturers will challenge the patent’s validity, and Aurobindo will also contest the infringement finding. Acadia will defend both rulings. Listen for the distinction between challenging the patent itself and disputing whether a particular product meets its requirements.

Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Ltd. (No. 25-1875) — U.S. Court of Appeals for the Federal Circuit, argued November 9, 2026.